Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Repayment of subsidiary borrowings
Full or partial repayment or prepayment of outstanding borrowings of the company's subsidiaries.
No lots distribution added yet.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
No peer comparisons added yet.
Global Health Limited, incorporated in 2004 and based in Delhi NCR, operates a network of tertiary and quaternary care hospitals under the widely recognized Medanta brand. The group runs four hospitals, in Gurugram, Indore, Ranchi and Lucknow, together housing well over two thousand beds and covering specialties such as cardiac sciences, neurosciences, oncology, digestive and hepatobiliary care, orthopaedics, liver transplant and kidney and urology care. The flagship Gurugram facility anchors a broader footprint built up over roughly two decades, staffed by more than a thousand doctors and supported by extensive diagnostic and clinical infrastructure. The company has continued to add capacity at its existing campuses and has stated plans to expand its installed bed count meaningfully over the following years as it deepens its presence in the North and East of India. Revenue and profitability have both grown strongly in the years leading up to listing, with a notable jump in earnings in the most recent full year before the offer. The company's growth strategy centers on scaling its multi-specialty hospital network, adding beds at existing campuses, and leveraging its reputation in complex tertiary care to draw patients from across the region.
Ahead of the offer, the company raised about Rs 661 crore from anchor investors, with participation from marquee names including the Government of Singapore, the Monetary Authority of Singapore and Nomura Trust, at the issue's upper price band of Rs 336 per share.
Source: RHP • Analysis provided for informational purposes
Last Updated: 18 July 2026, 11:52 PM
Strengths are not available
Risks are not available
Global Health Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.